Names & Terms You Will Hear
Plain-language meanings for the terms your care team may use.
| Term | Meaning |
|---|---|
| Niacin, or nicotinic acid. | The drug name for vitamin B3. High doses treat cholesterol. |
| Vitamin B3, or vitamin B-3. | The vitamin family name. Everyone needs a small amount from food. |
| Immediate-release niacin (Niacor). | The fastest-acting form. It causes the most flushing. |
| Extended-release niacin (Niaspan). | A once-daily form. Usually the preferred choice. |
| Sustained-release niacin (Slo-Niacin, Endur-acin). | An over-the-counter, slow-dissolving form. It carries the highest liver risk. |
| Advicor, niacin ER plus lovastatin. | A combination pill. Pulled from the US market in 2016. |
| Simcor, niacin ER plus simvastatin. | A second combination pill. Also pulled from the US market in 2016. |
| Tredaptive or Cordaptive, niacin plus laropiprant. | Niacin paired with a flush-blocking drug. Suspended across Europe in 2013. |
| Niacinamide, or nicotinamide. | NOT the same drug for cholesterol. It has no meaningful lipid effect. |
| Inositol hexanicotinate. | Sold as 'flush-free' or 'no-flush' niacin. It does not meaningfully lower cholesterol. |
| Nicotinamide riboside, or NMN. | NAD+ supplements sold for energy and longevity. Not lipid drugs. |
| GPR109A, also called HM74A. | The receptor niacin activates on skin cells. It causes the flush. |
| DGAT2. | A liver enzyme niacin blocks. This step lowers VLDL and LDL. |
| Lp(a), or lipoprotein(a). | A cholesterol particle set mostly by your genes. Niacin is one of the few drugs that lowers it. |
| AIM-HIGH, HPS2-THRIVE, and CDP. | The names of the major niacin trials in this guide, from 2011, 2014, and 1975. |
Niacinamide: treats deficiency. No cholesterol effect.
Inositol hexanicotinate, sold as "flush-free" niacin: does not lower cholesterol.
Nicotinamide riboside or NMN: sold for energy and longevity, not a lipid drug.
If the bottle does not say "niacin" or "nicotinic acid," it is not this drug.
What Is Niacin (Vitamin B3)?
- Niacin is vitamin B3. Your body needs a small daily amount, about 14 to 16 mg, to turn food into energy.
- At much higher doses, 1,500 to 2,000 mg a day, niacin also changes blood lipids. It raises HDL more than any other common drug. It also lowers LDL, triglycerides, and Lp(a).
- For decades, doctors prescribed high-dose niacin hoping it would prevent heart attacks. This idea is called the 'HDL hypothesis.'
- Large, rigorous trials tested that idea directly. Adding niacin to a working statin did not lower heart attacks, strokes, or deaths.
- Niacin is no longer FDA-approved combined with a statin. Current guidelines do not recommend it for routine heart protection.
- Niacin still has a narrow, real role. It treats true vitamin B3 deficiency. It also helps a few patients with severe triglycerides who cannot tolerate better-studied drugs.
Why It Matters
- For decades, doctors believed low HDL directly caused heart disease. A pill that raised HDL seemed like it should prevent heart attacks. Niacin raises HDL more than any other common drug.
- Niacin is cardiology's clearest example of a drug that improved a lab report without improving what matters: fewer heart attacks, strokes, and deaths.
- The 1975 win described below happened before statins existed. Once statins arrived, adding niacin on top added nothing in every large trial that followed.
- Two of the most rigorous niacin trials ever run, AIM-HIGH and HPS2-THRIVE, both added niacin to a statin. Neither found fewer heart attacks or strokes. HPS2-THRIVE also found real harm.
- This history changed how doctors think about lab numbers. A blood test moving the 'right' way is a clue. It is not proof that a drug helps you live longer.
1975: The Coronary Drug Project, Niacin's One Real Win
- The Coronary Drug Project ran from 1966 to 1975. It randomized 8,341 men with a prior heart attack to niacin, other lipid drugs, or placebo.
- This was entirely before statins existed. There was no other strong way to lower LDL at the time.
- The original results showed a modest drop in repeat heart attacks with niacin.
- A bigger finding came later. A 1986 follow-up found 15-year mortality was 11% lower with niacin than placebo, 52.0% versus 58.2%.
- This result built niacin's reputation. It is the only large trial that ever showed a mortality benefit, and it happened with no statins to compare against.
The HDL-Hypothesis Years: 'Raise the Good Cholesterol'
- Through the 2000s, doctors believed low HDL directly caused heart disease. A drug that raised HDL seemed like it should prevent heart attacks.
- ARBITER-2 (2004) and ARBITER-6-HALTS (2009) tested niacin added to a statin. Both used an ultrasound measure of artery-wall thickness as a stand-in for real heart attacks.
- ARBITER-2 found HDL rose 21% with niacin. The artery-wall measurement stayed flat with niacin and worsened with placebo, but the overall difference was not statistically significant.
- ARBITER-6-HALTS found niacin beat the drug ezetimibe on the same measurement. It was stopped early once that difference appeared.
- Both trials measured a stand-in, not actual heart attacks or strokes. That difference mattered once the bigger trials arrived.
2011-2014: Two Definitive Trials, No Benefit
- AIM-HIGH (2011) randomized 3,414 patients already on a statin, with LDL already at goal. Niacin raised HDL and lowered triglycerides further.
- The trial was stopped early. After about 3 years there was no difference in heart attacks, strokes, or cardiac deaths, 16.4% versus 16.2%.
- HPS2-THRIVE (2014) was far larger: 25,673 patients, followed almost 4 years. Niacin again improved LDL and HDL, and again showed no drop in major vascular events, 13.2% versus 13.7%.
- HPS2-THRIVE also found real harm. More new diabetes, and more serious stomach, muscle, skin, infection, and bleeding problems, with niacin than placebo.
- Both trials tested the exact situation many patients were in: a working statin, with niacin added for low HDL. Neither found a benefit worth the risk.
The Aftermath: Withdrawals and a New 2024 Signal
- The HPS2-THRIVE result moved fast into regulatory action. Europe suspended niacin-laropiprant products, Tredaptive and its twins, starting January 2013 and finalized in March 2013.
- In the US, the FDA withdrew the niacin-statin combination pills Advicor and Simcor on April 18, 2016. It cited the AIM-HIGH and HPS2-THRIVE evidence.
- Both products had already left pharmacy shelves in late 2015.
- Current cholesterol guidelines reflect this evidence. Niacin has only a mild LDL effect. Trials do not support adding it to a statin for routine prevention.
- In 2024, Cleveland Clinic researchers linked a niacin breakdown product called 4PY to higher rates of heart attack, stroke, and death. It also promoted blood-vessel inflammation in lab studies.
- This 2024 finding is an early signal, not a finished story. It has not changed any guideline. It may explain, at a biology level, why niacin's HDL boost never helped patients.
Risk Factors
Some situations raise your risk of harm from niacin. Knowing yours helps your care team watch more closely.
| Risk Factor | Why It Increases Risk |
|---|---|
| Already on a statin with LDL at goal. | This is the exact case tested in AIM-HIGH and HPS2-THRIVE. Niacin added no further protection. |
| Diabetes or prediabetes. | Niacin raises blood sugar. HPS2-THRIVE found more new diabetes diagnoses with niacin. |
| Gout or high uric acid. | Niacin can raise uric acid and trigger gout flares. |
| Liver disease or heavy alcohol use. | Niacin is processed by the liver. Sustained-release forms carry the most risk here. |
| Taking simvastatin or lovastatin. | The FDA label warns that niacin raises muscle-injury risk with these two statins. |
| Active or past peptic ulcer disease. | Niacin can reactivate ulcers. Active ulcers are a contraindication on the FDA label. |
| Buying niacin over the counter. | OTC niacin has no medical supervision of dose or form. Patients often pick the riskiest or the least useful form by accident. |
Treatment Options
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
- Niacin is no longer FDA-approved as a combination pill with a statin. Advicor and Simcor were pulled from the US market in 2016.
- Doctors prescribe niacin today for two narrow reasons. One is a confirmed niacin deficiency. The other is severe triglycerides that other drugs have not controlled.
- Extended-release niacin, such as Niaspan, is usually preferred. It causes less liver injury than sustained-release forms.
- Dosing starts low, often 500 mg. It increases slowly over several weeks, toward 1,500 to 2,000 mg a day.
- A low dose of aspirin about 30 minutes before your niacin dose can blunt the flush.
- Blood tests check your liver, blood sugar, and uric acid before starting niacin, and periodically afterward.
- If you already take over-the-counter niacin, bring the bottle to your next visit. We need to know exactly which form and dose you take.
The Niacin Forms, Compared
| Form | Lipid Effect | Flushing | Liver Risk | Verdict |
|---|---|---|---|---|
| Immediate-release (Niacor) | Full effect: raises HDL, lowers LDL and triglycerides | Most of all forms | Lowest of the three prescription forms | Works, but flushing limits use |
| Extended-release (Niaspan) | Full effect, dose-dependent | Less than immediate-release | Low to moderate | Best balance - the usual choice |
| Sustained-release (Slo-Niacin - OTC) | Full effect | Least of the three | Highest - avoid swapping in for immediate-release | Most liver risk for the flushing it saves |
| Flush-free (inositol hexanicotinate) | None shown in trials | Minimal | Low | Does not lower cholesterol - skip it |
| Niacinamide (nicotinamide) | None - a different drug entirely | None | Low | Not a cholesterol drug at all |
Related Guides
- Lp(a), the particle niacin also lowers: see the Lipoprotein(a) guide.
- Statins, the foundation of cholesterol treatment: see the Statins guide.
- High triglycerides on their own: see the Triglycerides guide.
- What your cholesterol panel means: see the Understanding Cholesterol guide.
- Supplements people try for their heart: see the Dietary Supplements & Heart Health guide.
Comfort Measures at Home (No Medication Needed)
These simple steps support healing and ease symptoms. Use them alongside any medication your doctor prescribes.
- Take your dose with a low-fat snack, not on an empty stomach. This alone reduces flushing for many people.
- Skip hot showers, hot drinks, spicy food, and alcohol around dose time. All of these make the flush worse.
- A bedtime dose lets most of the flush happen while you sleep.
- Start low and go slow. Rushing the dose increase is the most common reason people quit niacin.
- Do not switch niacin brands or forms without checking with your doctor. The forms are not interchangeable at the same dose.
- Keep every lab appointment. Liver, blood sugar, and uric acid checks catch problems early.
Risks, Benefits, and Alternatives
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
Every choice has trade-offs. Use this table to start the shared decision conversation with your care team.
| Option | Risks | Benefits | Alternatives |
|---|---|---|---|
| Prescription niacin added to a statin for low HDL or high triglycerides. | Flushing and itching. Liver enzyme changes, more with sustained-release. Raised blood sugar and uric acid. Upset stomach. Can worsen ulcers. Rare vision changes. Higher muscle-injury risk with certain statins. | Raises HDL more than any other common drug. Lowers Lp(a) too. None of this lowered heart attacks or strokes in the largest trials. | A statin alone, at the right dose. Ezetimibe or a PCSK9-class drug if LDL is not at goal. Icosapent ethyl or a fibrate for high triglycerides. |
| Niacin for a confirmed vitamin B3 deficiency. | Flushing at high doses. The deficiency itself can be severe if it is missed. | Directly corrects a true nutrient deficiency, usually fast. | Niacinamide, which fixes the deficiency without flushing or a cholesterol effect. |
| Niacin for severe triglycerides, when other drugs are not enough. | The same side effects listed above: liver, blood sugar, uric acid, stomach, flushing. | Can lower triglycerides further after a fibrate, omega-3, and statin have not done enough. | Icosapent ethyl and fibrates are usually tried first. |
| Self-treating with over-the-counter niacin. | No monitoring of your liver, blood sugar, or uric acid. Easy to pick the wrong form by accident. | None proven. This is the unsupervised pattern that has not prevented heart attacks in any modern trial. | Talk with your cardiologist about whether any cholesterol drug is right for you. |
Common Misconceptions
| Myth | Reality |
|---|---|
| It raises 'good' cholesterol, so it must help my heart. | Raising HDL with niacin did not lower heart attack or stroke risk in the largest trials. A better lab number is not the same as a better outcome. |
| Flush-free niacin is the same thing, just gentler. | 'Flush-free' niacin does not meaningfully change cholesterol in trials. It is a different molecule. |
| It's a vitamin, so any dose is safe. | Your body needs about 14 to 16 mg a day. Cholesterol doses are 1,500 to 2,000 mg, over 100 times higher, with real risks. |
| Niacinamide works the same way for cholesterol. | Niacinamide treats vitamin B3 deficiency well. It has no meaningful cholesterol effect. |
| The flush means it's working. | Flushing comes from a separate skin reaction. It does not track with how well your lipids are responding. |
| If my doctor won't prescribe niacin, something is being withheld. | The opposite is true. Niacin was tested in tens of thousands of patients. That evidence is why it is no longer used routinely. |
Possible Complications
Knowing what can go wrong helps you spot problems early. Most complications are uncommon, especially with treatment.
| Where / What | What Can Happen |
|---|---|
| Hepatic, the liver. | Liver enzyme changes. Rarely, severe liver injury. Risk is highest with sustained-release niacin. |
| Endocrine and metabolic. | Raised blood sugar. New-onset diabetes. HPS2-THRIVE found both more often with niacin. |
| Musculoskeletal. | Muscle injury, called myopathy. Rarely, a severe form called rhabdomyolysis. Risk is highest with simvastatin or lovastatin. |
| Renal and rheumatologic. | Raised uric acid. Gout flares. |
| Gastrointestinal. | Upset stomach. Niacin can reactivate peptic ulcers. Active ulcers are a contraindication. |
| Ophthalmologic, the eyes. | Blurred vision. Rarely, swelling in the back of the eye. Both usually reverse if caught early. |
| Dermatologic, the skin. | Flushing and itching. The most common side effect. It usually eases with continued use. |
| Bleeding and infection. | An unexpected finding in HPS2-THRIVE: more serious bleeding and infections with niacin. |
Points to Know
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you remember nothing else, remember these key points.
- Niacin at vitamin doses, about 14 to 16 mg, has nothing to do with the much higher cholesterol-drug doses in this guide.
- 'Flush-free' niacin and niacinamide do not meaningfully lower cholesterol.
- Raising HDL with niacin has not been shown to lower heart attack or stroke risk on top of a statin.
- Niacin-statin combination pills, Advicor and Simcor, were pulled from the US market in 2016.
- Sustained-release, over-the-counter niacin carries the highest liver risk of any form.
- Never start, stop, or switch niacin forms without talking to your doctor.
- Aspirin about 30 minutes before a dose can blunt the flush.
- Niacin still has a real, narrow role: true deficiency, and select severe triglycerides.
When to Call Us — and When to Call 911
Shown in English for your safety — this section is not automatically translated. Confirm with your doctor or call the office.
If you are not sure, call. We would rather hear from you twice than miss a real problem.
- New yellow skin or eyes, dark urine, or unusual tiredness. Call us the same day.
- New muscle pain, tenderness, or weakness, especially with a statin. Call us today.
- Blurred vision or a new blind spot. Call us for a prompt eye check.
- Joint pain and swelling, especially the big toe. Call us.
- Black stools, vomiting blood, or severe stomach pain. Call 911 or go to the ER.
- New or worse thirst and urination with diabetes or prediabetes. Call us.
- Questions about switching niacin forms, doses, or OTC niacin. Call us before making a change.
Trusted Resources
Independent, evidence-based pages we recommend for deeper reading.
- Mayo Clinic - Niacin to Improve Cholesterol Numbers — Patient-friendly overview of prescription niacin for cholesterol, dosing, and side effects.
- MedlinePlus - Niacin for Cholesterol — US National Library of Medicine patient instructions, including the current evidence that niacin does not add benefit to statin therapy.
- Cleveland Clinic - Niacin (Vitamin B3): Uses and Benefits — Overview of niacin's vitamin and prescription uses, dosing forms, and precautions.
- NIH Office of Dietary Supplements - Niacin Fact Sheet for Consumers — Federal reference on niacin's role as a vitamin, dietary sources, and the flushing reaction at supplement doses.
Sources Used to Build This Guide
- Coronary Drug Project Research Group. JAMA 1975;231(4):360-381. PMID 1088963. [Randomized Controlled Trial] — Niacin's one positive outcome trial. Run in 8,341 men before statins existed.
- Canner PL et al. JACC 1986;8(6):1245-1255. PMID 3782631. [Long-term follow-up study] — The 15-year CDP follow-up. Niacin's death rate was 11% lower than placebo.
- Taylor AJ et al. ARBITER 2. Circulation 2004;110(23):3512-3517. PMID 15537681. [Randomized Controlled Trial (surrogate endpoint)] — HDL rose 21% with niacin. The main artery-thickness result was not significant.
- Taylor AJ et al. ARBITER 6-HALTS. NEJM 2009;361(22):2113-2122. PMID 19915217. [Randomized Controlled Trial (surrogate endpoint)] — Niacin beat ezetimibe on artery thickness. Flagged here as small and stopped early.
- Villines TC et al. JACC 2010;55(24):2721-2726. PMID 20399059. [Randomized Controlled Trial (surrogate endpoint, final report)] — Final ARBITER 6-HALTS results. Niacin beat ezetimibe on artery thickness.
- Boden WE et al. AIM-HIGH. NEJM 2011;365(24):2255-2267. PMID 22085343. [Randomized Controlled Trial] — Niacin added to a statin. No drop in heart attacks or strokes. Stopped early.
- HPS2-THRIVE Collaborative Group. NEJM 2014;371(3):203-212. PMID 25014686. [Randomized Controlled Trial] — The largest niacin trial. No benefit, plus more diabetes, bleeding, and infection.
- US FDA / Federal Register, 81 FR 22624. April 18, 2016. [Regulatory action] — The FDA order withdrawing Advicor and Simcor from the US market.
- European Medicines Agency. Tredaptive/Pelzont/Trevaclyn referral. 2013. [Regulatory action] — The EU order suspending niacin-laropiprant products after HPS2-THRIVE.
- Grundy SM, Stone NJ et al. Circulation 2019;139(25):e1082-e1143. PMID 30586774. [Clinical practice guideline] — The current US cholesterol guideline. Trials do not support niacin as add-on therapy.
- Kamanna VS, Kashyap ML. Am J Cardiol 2007;100(11A):S53-61. PMID 18047854. [Mechanistic review] — Source for niacin's DGAT2 mechanism and its effect on Lp(a).
- Kamanna VS et al. Curr Atheroscler Rep 2009;11(1):45-51. PMID 19080727. [Mechanistic review] — Confirms niacin's three-part mechanism: liver, HDL, and the skin flush.
- Benyo Z et al. Mol Pharmacol 2006;70(6):1844-1849. PMID 17008386. [Basic science / mechanistic study] — Shows skin Langerhans cells cause the niacin flush.
- Maciejewski-Lenoir D et al. J Invest Dermatol 2006;126(12):2637-2646. PMID 17008871. [Basic science / mechanistic study] — Identifies the flush receptor on skin Langerhans cells.
- Kamanna VS et al. Int J Clin Pract 2009;63(9):1369-1377. PMID 19691622. [Clinical review] — Source for the aspirin-before-dose tip that cuts flushing.
- Lauring B et al. Sci Transl Med 2012;4(148):148ra115. PMID 22914621. [Basic and clinical science] — Shows the flush receptor does not explain niacin's cholesterol effect.
- Xie S et al. Atherosclerosis 2025;408:120420. PMID 40618457. [Meta-analysis of randomized controlled trials] — Large meta-analysis. Niacin lowers Lp(a) by about 37% from baseline.
- Pieper JA. Am J Health Syst Pharm 2003;60(13 Suppl 2):S9-14. PMID 12901025. [Pharmacology review] — Source for comparing flushing and liver risk across niacin forms.
- Dunatchik AP et al. J Clin Lipidol 2011;6(2):121-131. PMID 22385545. [Systematic review] — Confirms sustained-release niacin's higher liver-enzyme risk.
- Morgan JM et al. Am J Cardiol 1998;82(12A):29U-34U. PMID 9915660. [Randomized Controlled Trial] — Source for the dose-response lipid numbers for extended-release niacin.
- Keenan JM. J Clin Lipidol 2013;7(1):14-23. PMID 23351578. [Randomized Controlled Trial] — Trial proof that 'flush-free' niacin does not lower cholesterol.
- Fraunfelder FW et al. Br J Ophthalmol 1995;79(1):54-56. PMID 7880795. [Retrospective clinical study] — Source for niacin's eye side effects, including macular edema.
- Cziraky MJ et al. J Clin Lipidol 2012;6(2):102-108. PMID 23415428. [Observational cohort study] — Real-world muscle-injury rates for niacin and other lipid drugs.
- FDA-approved NIASPAN prescribing information. AbbVie Inc., via DailyMed/NLM. [FDA-approved drug labeling] — The drug label. Source for the ulcer, gout, liver, and statin warnings.
- Ferrell M et al. Nature Medicine 2024;30(2):424-434. PMID 38374343. [Translational research study] — The 2024 report linking niacin's 4PY metabolite to heart risk.
- Maki KC et al. J Clin Lipidol 2012;6(5):413-426. PMID 23009777. [Evidence review] — Supports niacin's remaining role in severe, high triglycerides.
- Ryali H et al. Cureus 2025;17(9):e92437. PMID 41111680. [Case report] — A modern pellagra case. Confirms the classic deficiency symptoms.